Testosterone replacement therapy (TRT)

TRT has genuine randomised human evidence, which puts it well ahead of most longevity clinic offerings, but the evidence supports narrower claims than the marketing does. TRAVERSE (n=5,246 men aged 45 to 80 with hypogonadal symptoms, testosterone under 300 ng/dL, and existing or high cardiovascular risk; NEJM 2023) found daily 1.62% testosterone gel non-inferior to placebo for major adverse cardiac events (7.0% vs 7.3%; HR 0.96, 95% CI 0.78 to 1.17). That is a safety result, not a benefit result: TRAVERSE showed TRT does not appear to raise MACE risk in that population, while also recording small excesses of atrial fibrillation, pulmonary embolism and fracture. The Australian T4DM trial (Wittert et al., Lancet Diabetes & Endocrinology 2021; n=1,007 men aged 50 to 74 with impaired glucose tolerance or new type 2 diabetes and testosterone at or below 14.0 nmol/L, explicitly WITHOUT pathological hypogonadism) found that two years of testosterone undecanoate added to a lifestyle programme cut two-year type 2 diabetes incidence by roughly 40%, with fat loss and strength gains. Notably, T4DM's own lead investigator cautioned that testosterone is not a substitute for lifestyle intervention, and follow-up reporting indicates the diabetes-prevention effect was not durable once treatment stopped. What the evidence does NOT show: no trial has demonstrated that TRT extends lifespan, reduces all-cause mortality, slows biological ageing, or improves any validated healthspan endpoint. There is no RCT evidence supporting testosterone in men with normal testosterone levels, and the long-term effects of decades-long supraphysiological or "optimisation" dosing outside diagnosed deficiency are untested. Fertility suppression is a real and sometimes irreversible consequence. The honest grade is: strong clinical evidence for symptom and metabolic outcomes in confirmed deficiency, no evidence for the longevity claim itself.

What it is

Plain-language explainer

Categories

Common questions

What is Testosterone replacement therapy (TRT)?

TRT has genuine randomised human evidence, which puts it well ahead of most longevity clinic offerings, but the evidence supports narrower claims than the marketing does. TRAVERSE (n=5,246 men aged 45 to 80 with hypogonadal symptoms, testosterone under 300 ng/dL, and existing or high cardiovascular risk; NEJM 2023) found daily 1.62% testosterone gel non-inferior to placebo for major adverse cardiac events (7.0% vs 7.3%; HR 0.96, 95% CI 0.78 to 1.17). That is a safety result, not a benefit result: TRAVERSE showed TRT does not appear to raise MACE risk in that population, while also recording small excesses of atrial fibrillation, pulmonary embolism and fracture. The Australian T4DM trial (Wittert et al., Lancet Diabetes & Endocrinology 2021; n=1,007 men aged 50 to 74 with impaired glucose tolerance or new type 2 diabetes and testosterone at or below 14.0 nmol/L, explicitly WITHOUT pathological hypogonadism) found that two years of testosterone undecanoate added to a lifestyle programme cut two-year type 2 diabetes incidence by roughly 40%, with fat loss and strength gains. Notably, T4DM's own lead investigator cautioned that testosterone is not a substitute for lifestyle intervention, and follow-up reporting indicates the diabetes-prevention effect was not durable once treatment stopped. What the evidence does NOT show: no trial has demonstrated that TRT extends lifespan, reduces all-cause mortality, slows biological ageing, or improves any validated healthspan endpoint. There is no RCT evidence supporting testosterone in men with normal testosterone levels, and the long-term effects of decades-long supraphysiological or "optimisation" dosing outside diagnosed deficiency are untested. Fertility suppression is a real and sometimes irreversible consequence. The honest grade is: strong clinical evidence for symptom and metabolic outcomes in confirmed deficiency, no evidence for the longevity claim itself.

How strong is the evidence for Testosterone replacement therapy (TRT)?

Clinical. There is human trial evidence, which is the strongest grade variis applies to a protocol.

Is Testosterone replacement therapy (TRT) approved in Singapore?

Health Sciences Authority position on record: Registered and prescription-only. Testosterone products are registered therapeutic products with HSA and classified as Prescription Only Medicines. Nebido (testosterone undecanoate 1,000 mg/4 mL) holds Singapore registration number SIN13281P, listed on the MOH National Drug Formulary as a Prescription Only Medicine, indicated for testosterone replacement therapy in adult males with testosterone deficiency confirmed by clinical features and biochemical testing. Other registered options in Singapore include testosterone gel and testosterone ester injections. Prescribing requires a licensed medical practitioner and biochemically confirmed deficiency; there is no HSA-approved indication for testosterone as an anti-ageing, performance or longevity-optimisation intervention, so use in men without confirmed deficiency is off-label.. An evidence grade and a regulatory approval are different questions.

Is Testosterone replacement therapy (TRT) approved in Australia?

Therapeutic Goods Administration position on record: Registered on the ARTG and Schedule 4 (prescription-only). Testosterone undecanoate 1,000 mg/4 mL is ARTG-registered as Reandron 1000 (ARTG 106946 ampoule, 213942 vial; sponsor Aspen Pharmacare Australia), with several later generics (Rejunon, Gonadron, Reanmed, Testosterone SUN); transdermal testosterone products are also registered. The TGA-approved indication is testosterone replacement therapy for confirmed testosterone deficiency / male hypogonadism established by clinical features and biochemical tests. PBS subsidy is Authority Required and tightly restricted: androgen deficiency with an established pituitary or testicular disorder, or, for men 40 and over without such a disorder, androgen deficiency confirmed on at least two separate morning blood samples (testosterone below 8 nmol/L, or 8 to 15 nmol/L with elevated LH). Testosterone is neither TGA-approved nor PBS-subsidised for age-related testosterone decline, "andropause", anti-ageing or performance optimisation; prescribing for those purposes is off-label and private-pay.. An evidence grade and a regulatory approval are different questions.

Which clinics offer Testosterone replacement therapy (TRT)?

2 clinics in the variis directory across Singapore and Australia have Testosterone replacement therapy (TRT) on record. Each is listed on this page with its own sourced profile.

What else is Testosterone replacement therapy (TRT) called?

Also known as TRT, androgen replacement, androgen replacement therapy, andropause treatment, male hormone therapy, testosterone therapy, testosterone optimisation.